Overview
FRNM market data
Price History
FRNM price chart
Valuation & Profitability
- P/E (TTM)
- 1,118.35 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.29 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.97 – $14.26 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $119.8M.
Company News
Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18Benzinga · Aug 14, 2026, 4:27 PM
8-K/A filing — Freenome, Inc. (FRNM)SEC EDGAR · Aug 13, 2026, 9:28 PM
Freenome Receives FDA Breakthrough Device Designation For Its Investigational Lung Cancer Screening Test SimpleScreen LungBenzinga · Aug 12, 2026, 1:02 PM
Freenome shares are trading higher after the company announced FDA approval for its SimpleSreen CRC blood-based screening test.Benzinga · Jul 27, 2026, 1:03 PM
Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone PaymentBenzinga · Jul 27, 2026, 12:06 PM